Company profile: Immunic Therapeutics
1.1 - Company Overview
Company description
- Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
Products and services
- IMU-381: A next-generation, preclinical-stage molecule aimed at addressing gastrointestinal diseases, expanding Immunic’s pipeline of selective oral immunology therapies
- IMU-856: A small-molecule targeting Sirtuin 6 to restore intestinal barrier function and regenerate bowel epithelium, with potential use in gastrointestinal diseases like celiac disease
- Vidofludimus Calcium (IMU-838): An oral drug in development combining neuroprotective, anti-inflammatory, and anti-viral effects to treat multiple sclerosis and other chronic inflammatory and autoimmune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunic Therapeutics
Alumis
HQ: United States
Website
- Description: Provider of precision medicine solutions focused on the discovery, development, and treatment of autoimmune disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alumis company profile →
Gossamer Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development of novel and differentiated therapeutic products, including seralutinib for pulmonary arterial hypertension in Phase 3 clinical trials, and offering clinical trials and an expanded access program for investigational medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gossamer Bio company profile →
Salzman Group
HQ: United States
Website
- Description: Provider of global drug development and biotechnology services focused on transformative pharmaceutical innovation, creating and developing its own drugs and those of others, serving both as an internal research engine and as a boutique contract service organization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salzman Group company profile →
ChemoCentryx
HQ: United States
Website
- Description: Provider of orally administered small-molecule therapeutics targeting chemokine and related chemo-attractant receptors for inflammatory and autoimmune diseases and cancer, focusing on the discovery, development and commercialization of new medications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ChemoCentryx company profile →
Kezar Life Sciences
HQ: United States
Website
- Description: Provider of drug discovery and development focused on protein homeostasis, offering Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for autoimmune diseases via immune modulation without direct immunosuppression, and KZR-261, a first-in-class Sec61 translocon inhibitor for advanced/metastatic solid tumors that blocks key secreted proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kezar Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunic Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunic Therapeutics
2.2 - Growth funds investing in similar companies to Immunic Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunic Therapeutics
4.2 - Public trading comparable groups for Immunic Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →